-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Pfizer Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$41.91B | $81.29B | $100.33B | $58.50B |
| Cost of Revenue |
|
$8.69B | $30.82B | $34.34B | $29.69B |
| Gross Profit |
|
$33.22B | $50.47B | $65.99B | $28.81B |
| Research & Development |
|
$9.41B | $13.83B | $11.43B | $10.68B |
| Selling,General & Administrative |
|
$11.62B | $12.70B | $13.68B | $14.77B |
| Operating Expense |
|
$24.46B | $30.23B | $28.71B | $25.45B |
| Operating Income |
|
$10.63B | $24.83B | $40.03B | $3.36B |
| Net Income |
|
$7.02B | $21.98B | $31.37B | $2.12B |
Pfizer Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$12.22B | $31.07B | $22.73B | $12.69B |
| Inventories |
|
$8.05B | $9.06B | $8.98B | $10.19B |
| Total Current Assets |
|
$35.07B | $59.69B | $51.26B | $43.33B |
| Property,Plant and Equipment |
|
$13.90B | $14.88B | $16.27B | $21.86B |
| Goodwill |
|
$49.58B | $49.21B | $51.38B | $67.78B |
| Total Assets |
|
$154.23B | $181.48B | $197.21B | $226.50B |
| Total Liabilities |
|
$90.76B | $104.01B | $101.29B | $137.21B |
| Retained Earnings |
|
$96.77B | $103.39B | $125.66B | $118.35B |
| Total Shareholder Equity |
|
$63.24B | $77.20B | $95.66B | $89.01B |
| Common Stock |
|
$470.00M | $473.00M | $476.00M | $478.00M |
Pfizer Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$4.78B | $5.19B | $5.06B | $6.29B |
| Dividends Payout |
|
-$8.44B | -$8.73B | -$8.98B | -$9.25B |
| Capital Expenditures (Capex) |
|
-$2.79B | -$2.71B | -$3.24B | -$3.91B |
| Free Cash Flow (FCF) |
|
$11.61B | $29.87B | $26.03B | $4.79B |
Pfizer Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$33.22B | $50.47B | $65.99B | $28.81B |
| Gross Profit Margin (%) |
|
79.26% | 62.08% | 65.77% | 49.25% |
| Operating Income |
|
$10.63B | $24.83B | $40.03B | $3.36B |
| Operating Income Margin (%) |
|
25.37% | 30.55% | 39.90% | 5.74% |
| Net Income |
|
$7.02B | $21.98B | $31.37B | $2.12B |
| Net Income Margin (%) |
|
16.75% | 27.04% | 31.27% | 3.62% |
| EBITDA |
|
$13.17B | $30.79B | $41.03B | $9.56B |
| EBITDA Margin (%) |
|
33.56% | 35.10% | 43.50% | 16.34% |
Pfizer Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
11.10% | 28.47% | 32.79% | 2.38% |
| Return on Assets (ROA) |
|
4.55% | 12.11% | 15.91% | 0.94% |
| Debt to Equity |
|
62.99% | 47.92% | 36.45% | 80.76% |
| Debt to total asset |
|
25.83% | 20.39% | 17.68% | 31.74% |
| Enterprise value to revenue |
|
5.75 | 4.50 | 3.21 | 3.94 |
| Enterprise value to EBITDA |
|
18.30 | 11.88 | 7.84 | 24.11 |
| Enterprise value |
|
$240.97B | $365.79B | $321.81B | $230.45B |
| Cash to Debt |
|
36.16% | 88.06% | 83.93% | 12.10% |
| Tax Rate (%) |
|
6.36% | 7.62% | 9.58% | -105.29% |
| Payout Ratio |
|
120.23% | 39.72% | 28.63% | 436.39% |
Related company
